




# avextra

*In under four years, Avextra has become one of the only leading cannabis companies with vertically integrated EU assets that deliver proprietary cannabis-based medicine to serve federally regulated medical markets.*

*By tapping into the wealth of experience both practitioners and pharmacists are gaining as they treat significant unmet patient needs in specific indications, Avextra has developed an innovative clinical plan and created a rich pipeline for future regulator-approved cannabis-based medicine.*

***Our vision: to understand and harness the therapeutic potential of the cannabis plant and thereby improve the quality of life for patients around the world.***

## Our Assets Strategically Developed Across Europe



### Our Cultivation

- \_ Portugal (operational)

### Production/Manufacturing


- \_ Germany GMP manufacturing facility
- \_ Processing space in Germany (largest in industry & scaleable)

### Production/IP

- \_ R&D license in Germany
- \_ R&D license in Portugal (pending inspection)

### Distribution

- \_ Germany
- \_ UK (Ownership in Integro Medical Clinics)
- \_ Italy
- \_ Switzerland (coming soon)
- \_ Poland (coming soon)



## Avextra controls the entire value chain:

### FROM GENETIC SELECTION TO PRODUCT INNOVATION



### Genetic Selection and Cultivation

We have a 600 m<sup>2</sup> purpose-built cultivation facility on 250 ha of land in Portugal to cultivate rare genetics for indication-based formulations.

### Product Development and R&D

Focused development of novel extract-based product innovations.

### Production and Manufacturing

10,000 m<sup>2</sup> state-of-the-art GMP manufacturing facility in Germany and a highly qualified team with 75 years of experience in botanical extraction of plant-based medicines.

### Distribution

Our products are already present in four of the biggest EU markets with expansion plans in place. We have one of the largest sales teams in Germany, equipped with exceptional connections.

### Clinical Pipeline

Clinical Program in place to gather product-specific data for future commercials, with three clinical programs starting in 2023.

## Our Leadership Team



**Dr. Bernhard Babel,**  
Co-CEO

Dr. Babel has more than 15 years of international experience in Regulatory Affairs & Business Development. Before founding Avextra, he was a partner at McKinsey and CEO at Risk Dynamics.



**David Reckeweg-Lecompte,**  
Co-CEO

As Managing Director of Dr. Reckeweg & Co. GmbH, David has extensive experience in plant-based extraction as well as global business development. David has been President of the European Coalition on Homeopathic & Anthroposophic Medicinal Products since 2019.



**Neil Smith,** COO

During his career in the financial services sector, Neil has held various senior positions and served as Chief Operating Officer for Deutsche Bank.



**Marla Luther,**  
CSO & Marketing

Marla is one of the pioneers and most successful executives of the medical cannabis industry in Germany, successfully leading Tilray's market entrance as CEO.

**Looking for more information? Get in touch.**  
[investors@avextra.com](mailto:investors@avextra.com)

[avextra.com](https://avextra.com)